You are here
REGENX BIOSCIENCES, LLC
UEI: N/A
# of Employees: 0
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Genetically-delivered Bevacizumab for Treatment of Wet Age-Related Macular Degene
Amount: $261,327.00DESCRIPTION (provided by applicant): The goal of this Phase I SBIR is the pre-clinical development of a novel gene-based delivery system for bevacizumab (anti-VEGF antibody) to treat wet age-related m ...
SBIRPhase I2013Department of Health and Human Services National Institutes of Health -
AAV Mediated Gene Transfer to the CNS for MPS I
Amount: $211,009.00DESCRIPTION (provided by applicant): Mucopolysaccharidosis type I (MPS I) is an autosomal recessive storage disease caused by the absence of a-L-iduronidase (IDUA), resulting in systemic accumulation ...
STTRPhase I2012Department of Health and Human Services National Institutes of Health -
Novel Adeno-Associated Viral Therapy for Wet Age-Related Macular Degeneration
Amount: $304,421.00DESCRIPTION (provided by applicant): The overall goal of this project is to develop a novel gene-based delivery system to treat neovascular age- related macular degeneration (wet AMD), a debilitating ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
Scalable Production of New Generation Adeno-Associated Virus Gene Therapy Vectors
Amount: $263,277.00DESCRIPTION (provided by applicant): The overall goal of this application is to develop a scalable production system for the manufacture of an adeno- associated virus (AAV) serotype 8-based gene thera ...
SBIRPhase I2010Department of Health and Human Services National Institutes of Health